April 2020 HSC Section 4 - Plastic and Reconstructive Problems

J A M A CAD D ERMATOL J ULY 2017

Adil and Godwin

Results, mean difference hair density/cm 2 (SD) * between baseline and follow-up

48 Dutasteride: 16.5 Placebo: 3.8

24 Dutasteride: 89.6 Placebo: 4.9

Follow-up, weeks

AGA , Androgenetic alopecia; LLLLT , low-level laser light therapy; NH , Norwood Hamilton scale; N/S , not specified; SD , standard deviation; SEM , standard error of the mean. *Standard deviation was used except where indicated. SEM and P values were used in some studies.

Article Sex Study population details Intervention group Control Placebo N = 17 Stough et al 2006 30 Men Mean age: 18-50 years Exclusion: illness that might confound the results of the study, surgical correction of hair loss, correction of hair loss Country: US AGA type: NH II-V Harcha et al 2014 31 Men Mean age: 38.5 years Exclusion: serum testosterone \ 250 ng/dL, Dutasteride 0.5 mg/day N = 17 (twin study) Dutasteride 0.5 mg/day N = 183 Placebo N = 183

unstable liver disease, malignancy within previous 5 years, prostate cancer before 50 years in a first-degree relative or serum prostate-specific antigen level [ 2.0 ng/

mL, breast cancer, global hair thinning, hair loss not caused by androgenetic alopecia, scarring of the scalp

Race: 55% Asian, 40% Hispanic, 5% white AGA type: NH types IIIv-V (except IVa, Va)

Supplementary Table I. Cont’d

98